A Performance Overview of Merck’s Hospital Acute Care Business

Merck & Co.’s (MRK) Bridion generated revenues of $217 million in the third quarter, which reflected a ~17% YoY (year-over-year) growth.

In the US and international markets, Bridion generated revenues of $96 million and $120 million, respectively, in the third quarter, which was a ~52% YoY growth and a ~1% YoY decline, respectively.

Bridion’s net revenues for the first nine months of the year were $661 million, reflecting a ~33% YoY growth.

Bridion primarily boosted Merck’s Hospital Acute Care business in the third quarter.

Merck’s Noxafil generated revenues of $188 million in the third quarter, which reflected a ~16% YoY growth.

In the US and international markets, Noxafil generated revenues of $89 million and $99 million, respectively, in the third quarter, which was a ~13% YoY growth and a ~19% YoY growth, respectively.

Noxafil’s net year-to-date revenues are $551 million, reflecting a ~21% YoY growth.

Invanz generated revenues of $137 million in the third quarter, reflecting a ~14% YoY decline.

Invanz generated revenues of $74 million and $62 million from sales in the US and international markets, respectively, in the third quarter, which reflected a ~20% YoY decline and a ~6% YoY decline, respectively.

Invanz reported year-to-date revenues of $437 million, a ~2% YoY decline.

In the third quarter, Cubicin reported revenues of $95 million, reflecting a ~4% YoY growth. Its revenues were $55 million and $40 million for sales in the US and international markets, respectively, in the third quarter, reflecting a ~33% YoY growth and a ~19% YoY decline, respectively.

Cubicin reported year-to-date revenues of $287 million, which was a ~1% YoY decline.

Cancidas generated revenues of $79 million in the third quarter, reflecting a ~16% YoY decline. In the US and international markets, Cancidas reported revenues of $2 million and $77 million, respectively.

Cancidas reported net revenues of $257 million for the first nine months of the year, which was a ~22% YoY decline.

Primaxin generated net revenues of $72 million in the third quarter, reflecting a ~1% YoY decline. Its net revenues for the first nine months of the year were $212 million, reflecting a ~3% YoY growth.